Discontinued — last reported Q2 '21
Debt - Unamortized Discount (Premium) and Issuance Costs, Net
Royalty Pharma Debt - Unamortized Discount (Premium) and Issuance Costs, Net decreased by 2.4% to $223.56M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 22.5%, from $182.55M to $223.56M. Over 5 years (FY 2020 to FY 2025), Debt - Unamortized Discount (Premium) and Issuance Costs, Net shows an upward trend with a 4.5% CAGR.
Analysis
How to read this metric
Changes reflect the issuance of new debt or the amortization of existing discounts/premiums, impacting future interest expense.
Detailed definition
This represents the net adjustment to the face value of debt, accounting for the difference between the issuance price a...
Peer comparison
Standard accounting adjustment for any company with significant long-term debt instruments on its balance sheet.
debt_unamortized_discount_premium_issuance_costsHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $174.44M | $209.33M | $203.93M | $198.86M | $193.80M | $188.74M | $183.68M | $178.62M | $173.56M | $168.81M | $164.72M | $160.62M | $197.98M | $192.62M | $187.57M | $182.55M | $177.50M | $234.27M | $229.08M | $223.56M |
| QoQ Change | — | +20.0% | -2.6% | -2.5% | -2.5% | -2.6% | -2.7% | -2.8% | -2.8% | -2.7% | -2.4% | -2.5% | +23.3% | -2.7% | -2.6% | -2.7% | -2.8% | +32.0% | -2.2% | -2.4% |
| YoY Change | — | — | — | — | +11.1% | -9.8% | -9.9% | -10.2% | -10.4% | -10.6% | -10.3% | -10.1% | +14.1% | +14.1% | +13.9% | +13.6% | -10.3% | +21.6% | +22.1% | +22.5% |
Debt - Unamortized Discount (Premium) and Issuance Costs, Net at Other Companies
Frequently Asked Questions
- What is Royalty Pharma's debt - unamortized discount (premium) and issuance costs, net?
- Royalty Pharma (RPRX) reported debt - unamortized discount (premium) and issuance costs, net of $223.56M in Q1 2026.
- How has Royalty Pharma's debt - unamortized discount (premium) and issuance costs, net changed year-over-year?
- Royalty Pharma's debt - unamortized discount (premium) and issuance costs, net increased by 22.5% year-over-year, from $182.55M to $223.56M.
- What is the long-term trend for Royalty Pharma's debt - unamortized discount (premium) and issuance costs, net?
- Over 5 years (2020 to 2025), Royalty Pharma's debt - unamortized discount (premium) and issuance costs, net has grown at a 4.5% compound annual growth rate (CAGR), from $183.42M to $229.08M.
- What does debt - unamortized discount (premium) and issuance costs, net mean?
- The net adjustment to debt value representing issuance costs and the difference between issuance price and face value.